Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;14(5):292-300.
doi: 10.1200/JOP.18.00063.

Contemporary Approaches to In-Transit Melanoma

Jennifer A Perone  1 , Nellie Farrow  1 , Douglas S Tyler  1 , Georgia M Beasley  1
Affiliations
Review

Contemporary Approaches to In-Transit Melanoma

Jennifer A Perone et al. J Oncol Pract. 2018 May.

Abstract

In-transit melanoma represents a distinct disease pattern of heterogeneous superficial tumors. Many treatments have been developed specifically for this type of disease, including regional chemotherapy and a variety of directly injectable agents. Novel strategies include the intralesional delivery of oncolytic viruses and immunocytokines. The combination of intralesional or regional chemotherapy with systemic immune checkpoint inhibitors also is a promising approach. In the current review, we examine the general management of the workup of patients with in-transit disease, the range of available therapies, and recommendations for specific therapies for an individual patient.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Algorithm for in-transit (IT) melanoma. Underlined therapies are approved therapies. (*) Therapies still under investigation. ILI, isolated limb infusion; HILP, hyperthermic isolated limb perfusion; HN, head and neck; LN, lymph node; SLNB, sentinel lymph node biopsy; T-VEC, talimogene laherparepvec.
Fig 2.
Fig 2.
Algorithm for recurrent/treatment failure in-transit (IT) melanoma. ILI, isolated limb infusion; HILP, hyperthermic isolated limb perfusion; HN, head and neck; LN, lymph node.
See this image and copyright information in PMC

Comment in

References

    1. Pawlik TM, Ross MI, Thompson JF, et al. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005;23:4588–4590. - PubMed
    1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the skinin Amin MB, Edge SB, Greene FL, et al.eds): AJCC Cancer Staging Manual ed 8New York, NY: Springer International Publishing; 2017563‐585
    1. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12:587–596. - PubMed
    1. Read RLH, Haydu L, Saw RP, et al. In-transit melanoma metastases: Incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;22:475–481. - PubMed
    1. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97. - PubMed

Publication types